Category: Uncategorized

Salarius Pharmaceuticals CEO Issues Letter to Stockholders

Back

Salarius Pharmaceuticals CEO Issues Letter to Stockholders

Read More

Salarius Pharmaceuticals Adds Two Mayo Clinic Sites to its Ongoing Phase 1/2 Trial of Seclidemstat as a Treatment for Ewing’s Sarcoma and FET-Rearranged Sarcomas

Back

Salarius Pharmaceuticals Adds Two Mayo Clinic Sites to its Ongoing Phase 1/2 Trial of Seclidemstat as a Treatment for Ewing’s Sarcoma and FET-Rearranged Sarcomas

Read More

Salarius Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update

Back

Salarius Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update

Read More

Salarius Pharmaceuticals Adds Seattle Cancer Care Alliance and Oregon Health & Sciences as Clinical Sites for its Ongoing Trial of Seclidemstat as a Treatment for Ewing Sarcoma and FET-Rearranged Sarcomas

Back

Salarius Pharmaceuticals Adds Seattle Cancer Care Alliance and Oregon Health & Sciences as Clinical Sites for its Ongoing Trial of Seclidemstat as a Treatment for Ewing Sarcoma and FET-Rearranged Sarcomas

Read More

Salarius Pharmaceuticals and VolitionRx Enter into R&D Collaboration Agreement

Back

Salarius Pharmaceuticals and VolitionRx Enter into R&D Collaboration Agreement

Read More

Salarius Pharmaceuticals to Host Second Quarter 2022 Financial Results and Business Update Conference Call on Monday, August 8, 2022

Back

Salarius Pharmaceuticals to Host Second Quarter 2022 Financial Results and Business Update Conference Call on Monday, August 8, 2022

Read More

Salarius Pharmaceuticals to Participate in BIO International Convention 2022

Back

Salarius Pharmaceuticals to Participate in BIO International Convention 2022

Read More

Salarius Pharmaceuticals to Present at H.C. Wainwright Global Investment Conference

Back

Salarius Pharmaceuticals to Present at H.C. Wainwright Global Investment Conference

Read More

Salarius Pharmaceuticals Reports Business Highlights with First Quarter 2022 Financial Results

Back

Salarius Pharmaceuticals Reports Business Highlights with First Quarter 2022 Financial Results

Read More

Salarius Pharmaceuticals Completes SP-3164 Pre-Investigational New Drug Meeting Process with the U.S. Food and Drug Administration

Back

Salarius Pharmaceuticals Completes SP-3164 Pre-Investigational New Drug Meeting Process with the U.S. Food and Drug Administration

Read More